Eli Lilly and Company $LLY Stock Purchased by GAMMA Investing LLC

Key Points

• GAMMA Investing increased its Eli Lilly stake by 9.8% in the third quarter, bringing its holdings to 28,383 shares valued at approximately $32.8 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $1,313.43; several firms recently raised their targets, including JPMorgan to $1,500.
• Eli Lilly reported strong quarterly growth, with revenue up 47.7% year over year and EPS of $8.38 versus the $6.40 consensus estimate. However, the stock trades at roughly 39 times earnings, leaving it exposed to high-growth expectations, pricing pressure and GLP-1 competition.

GAMMA Investing LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,383 shares of the company's stock after purchasing an additional 2,538 shares during the period. Eli Lilly and Company comprises approximately 1.1% of GAMMA Investing LLC's investment portfolio, making the stock its 13th biggest holding. GAMMA Investing LLC's holdings in Eli Lilly and Company were worth $32,841,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Galvin Gaustad & Stein LLC raised its stake in shares of Eli Lilly and Company by 347.0% during the 3rd quarter. Galvin Gaustad & Stein LLC now owns 6,115 shares of the company's stock valued at $7,076,000 after buying an additional 4,747 shares during the last quarter. Grove Bank & Trust boosted its stake in shares of Eli Lilly and Company by 0.5% in the third quarter. Grove Bank & Trust now owns 7,609 shares of the company's stock worth $8,804,000 after buying an additional 38 shares during the last quarter. Wisconsin Wealth Advisors LLC acquired a new stake in Eli Lilly and Company during the third quarter worth about $966,000. Financial Enhancement Group LLC grew its holdings in Eli Lilly and Company by 1.2% during the third quarter. Financial Enhancement Group LLC now owns 4,200 shares of the company's stock worth $4,993,000 after acquiring an additional 50 shares during the period. Finally, Hamilton Capital LLC raised its position in Eli Lilly and Company by 5.5% during the third quarter. Hamilton Capital LLC now owns 1,061 shares of the company's stock valued at $1,228,000 after acquiring an additional 55 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on LLY shares. BMO Capital Markets restated an "outperform" rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Sanford C. Bernstein boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research note on Tuesday, July 14th. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a report on Friday, August 7th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a research report on Monday, September 28th. Finally, Leerink Partners lifted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $1,313.43.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on Eli Lilly (LLY) to $1,440 from $1,410 and maintained an “overweight” rating, implying substantial upside from recent trading levels. Cantor Fitzgerald price target report
• Positive Sentiment: Lilly and Nvidia committed up to $1 billion to establish an artificial-intelligence drug-discovery laboratory. The initiative could improve research efficiency and strengthen Lilly’s future pipeline, although financial benefits are likely long term. Nvidia and Eli Lilly AI drug discovery lab
• Positive Sentiment: Investor commentary remains bullish on Lilly’s growth beyond Mounjaro and Zepbound, highlighting retatrutide, manufacturing expansion, oncology products and other pipeline opportunities. Retatrutide’s potential for greater weight loss could provide another major growth driver if late-stage trials and regulatory review succeed. Eli Lilly obesity business analysis
• Positive Sentiment: New early-stage studies are expanding Lilly’s obesity and Alzheimer’s pipelines, while its oncology portfolio—including Jaypirca, Inluriyo and Retevmo—could offset slower growth from mature products. Lilly obesity drug trial
• Neutral Sentiment: Lilly signed a research collaboration and licensing agreement with InnoCare Pharma covering as many as five drug targets. The deal broadens potential discovery opportunities, but the targets remain early-stage and do not yet provide near-term revenue visibility. InnoCare and Eli Lilly deal
• Negative Sentiment: LLY remains valued at roughly 40 times trailing earnings, leaving the shares sensitive to slowing growth, pricing pressure and stronger competition in the GLP-1 market. Recent commentary argues the long-term opportunity is attractive but acknowledges that expectations are already high.
• Negative Sentiment: New WHO childhood-obesity guidance may increase scrutiny around the use, access and long-term safety of obesity medicines, creating regulatory and reimbursement uncertainty for Lilly and Novo Nordisk. WHO childhood obesity guidelines

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,169.77 on Friday. The stock has a 50 day moving average of $1,173.78 and a two-hundred day moving average of $1,096.45. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65. The firm has a market cap of $1.10 trillion, a P/E ratio of 39.25, a price-to-earnings-growth ratio of 1.46 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the company posted $6.31 earnings per share. The business's revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.